Clinical testing showed a high tolerance of cirmtuzumab in relapsed CLL patients, moreover, the treatment inhibited RhoA and HS1 activation via the inhibition of ROR1 [105, 132]. This evidence concerns the gene ROR1 and B-cell chronic lymphocytic leukemia.